References
- Kemeny N. E. Regional chemotherapy of colorectal cancer. Eur. J. Cancer 1995; 31A(7)1271–1276, [PUBMED], [INFOTRIEVE]
- Arai Y., Inaba Y., Takeuchi Y., Ariyoshi Y. Intermittent hepatic arterial infusion of high-dose 5FU on a weekly schedule for liver metastases from colorectal cancer. Cancer Chemother. Pharmacol. 1997; 40(6)526–530, [PUBMED], [INFOTRIEVE], [CROSSREF], [CSA]
- Sugihara K. Continuous hepatic arterial infusion of 5-fluorouracil for unresectable colorectal liver metastases: phase II study. Surgery 1995; 117(6)624–628, [PUBMED], [INFOTRIEVE], [CSA]
- Arai Y., Sone Y., Tohyama N., Inaba Y., Kohno S., Kido C., Ariyoshi Y. Hepatic arterial infusion for unresectable liver metastases from gastric cancer. Proc. Am. Soc. Clin. Oncol. 1992; 11: 176
- Tarazov P. G. Transcatheter therapy of gastric cancer metastatic to the liver: preliminary results. J. Gastroenterol. 2000; 35(12)907–911, [PUBMED], [INFOTRIEVE], [CROSSREF]
- Kumada T., Arai Y., Itoh K., Takayasu Y., Nakamura K., Ariyoshi Y., Tajima Y. Phase II study of combined administration of 5-fluorouracil, epirubicin and mitomycin-C by hepatic artery infusion in patients with liver metastases of gastric cancer. Oncology 1999; 57(3)216–223, [PUBMED], [INFOTRIEVE], [CROSSREF], [CSA]
- Tono T., Ukei T., Masutani S., Shibata K., Ohzato H., Hasuike Y., Monden T. Management of hepatic arterial infusion (HAI) following prophylactic regional chemotherapy in patients undergone curative resection of colorectal liver metastases. Surg. Today 2003; 33(9)679–683, [PUBMED], [INFOTRIEVE], [CROSSREF], [CSA]
- Grem J. L., Tutsch K. D., Simon K. J., Alberti D. B., Willson J. K., Tormeny D. C., Swaminathan S., Trump D. L. Phase I study of taxol administered as a short iv infusion daily for 5 days. Cancer Treat. Rep. 1987; 71(12)1179–1184, [PUBMED], [INFOTRIEVE], [CSA]
- Tono T., Hasuike Y., Ohzato H., Takatsuka Y., Kikkawa N. Limited but definite efficacy of prophylactic hepatic arterial infusion chemotherapy following curative resection of colorectal liver metastases. Cancer 2000; 88(7)1549–1556, [PUBMED], [INFOTRIEVE]
- Yamada Y., Shirao K., Ohtsu A., Boku N., Hyodo I., Saito H., Miyata Y., Taguchi T. Phase II trial of paclitaxel by three-hour infusion for advanced gastric cancer with short premedication for prophylaxis against paclitaxel-associated hypersensitivity reactions. Ann. Oncol. 2001; 12(6)1133–1137, [PUBMED], [INFOTRIEVE], [CROSSREF]
- Yamaguchi K., Tada M., Horikoshi N., Otani T., Takiguchi H., Saitoh S., Kanamaru R., Kasai Y., Koizumi W., Sakata Y., Taguchi T. Phase II study of paclitaxel with 3-h infusion in patients with advanced gastric cancer. Gastric Cancer 2002; 5(1)90–95, [PUBMED], [INFOTRIEVE], [CROSSREF], [CSA]
- Seidman A. D., Hudis C. A., Albanel J., Tong W., Tepler I., Currie V., Moynahan M. E., Theodoulou M., Gollub M., Baselga J., Norton L. Dose-dense therapy with weekly 1-hour paclitaxel infusions in the treatment of metastatic breast cancer. J. Clin. Oncol. 1998; 16(10)3353–3361, [PUBMED], [INFOTRIEVE]
- Kaern J., Baekelandt M., Trope C. G. A phase II study of weekly paclitaxel in platinum and paclitaxel-resistant ovarian cancer patients. Eur. J. Gynaecol. Oncol. 2002; 23(5)383–389, [PUBMED], [INFOTRIEVE], [CSA]
- Chang Y., Li L. L., Wu C., Liu T., Lui W., P'eng F., Chi C. Paclitaxel-induced apoptosis in human gastric carcinoma cell lines. Cancer 1996; 77(1)14–18, [PUBMED], [INFOTRIEVE], [CROSSREF]
- Walton G. D., Schreeder M. T., Rizzo J., Jobe D., Kuhn J. Hepatic artery administration of paclitaxel. Cancer Investig. 1999; 17(2)118–120, [CSA]